VIVS
VivoSim Labs, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.16
+0.38%Oct 16, 2026, 20:14 UTC
VivoSim Labs, INC. amended its lease with San Diego Inspire 2, LLC, surrendering Suite 202 effective February 28, 2027, extending the Suite 100 lease through April 30, 2028, setting monthly base rent at $43,072.85, and providing $86,145.70 in rent abatements.
Oct 6, 2026, 20:14 UTC
VivoSim Labs elected Adam Stern as a Class III director, effective September 30, 2026.
Oct 6, 2026, 20:14 UTC
VivoSim Labs elected Keith Murphy as a Class III director, effective September 30, 2026.
Sep 16, 2026, 12:05 UTC
VivoSim Labs unveiled new NAMkind drug toxicity data at EUROTOX 2026 in Vienna, demonstrating predictive superiority in liver and gastrointestinal safety across small molecules and ADCs.
Source:Aug 21, 2026, 00:00 UTC
VivoSim Labs, Inc. received a notice from NASDAQ on August 17, 2026, stating that the company is not in compliance with Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum bid price of $1.00 per share, and the company has until February 16, 2027, to regain compliance.
Jul 21, 2026, 12:05 UTC
VivoSim enters the Chinese market with the first commercial sales of its NAMkind™ toxicology screening and efficacy testing services.
Source:Jul 17, 2026, 00:00 UTC
VivoSim Labs, Inc. signed a private placement agreement to sell pre-funded warrants and common warrants for its common stock to an undisclosed healthcare-focused institutional investor, with A.G.P./Alliance Global Partners acting as placement agent, for gross proceeds of approximately $4.0 million.
Source:Jul 15, 2026, 12:05 UTC
VivoSim Labs, Inc. announced that it received a $5 million milestone payment from Eli Lilly.
Source: